SCHEMBL6984533

SCHEMBL6984533

C[Si](C)(C)CCOCn1c(-c2cccc(C(F)(F)F)c2)nc(Br)c1Br

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 3/20 0.43
NR1H4 Q96RI1 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
POLB P06746 1/20 0.38
KDM4E B2RXH2 3/20 0.38
HSD17B10 Q99714 2/20 0.38
ALDH1A1 P00352 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
HTT P42858 2/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
GAA P10253 1/20 0.36
HPGD P15428 1/20 0.36
RAB9A P51151 2/20 0.36
MAPT P10636 2/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL66909 0.88 DGAT1 (0.47) DGAT1KDM4EALDH1A1LMNAALOX5AP
SCHEMBL67447 0.82 DGAT1 (0.40) DGAT1NPSR1POLBKDM4EHSD17B10
SCHEMBL6982954 0.80 DGAT1 (0.58) DGAT1NR1H4NPSR1POLBKDM4E
SCHEMBL68112 0.79 DGAT1 (0.41) DGAT1KDM4EHSD17B10ALDH1A1SMN1; SMN2
SCHEMBL23781131 0.74 DGAT1 (0.39) DGAT1POLBKDM4EHSD17B10ALDH1A1
SCHEMBL17810234 0.73 DGAT1 (0.46) DGAT1MAPTNPC1ALOX5APFEN1
SCHEMBL2685643 0.72 ADORA1 (0.47) DGAT1MEN1KMT2AMAPTADORA1
SCHEMBL19398619 0.72 KCNH2 (0.53) DGAT1ALDH1A1MEN1KMT2AGAA
SCHEMBL311704 0.72 CXCR1 (0.43) DGAT1NR1H4KDM4EHSD17B10ALDH1A1
SCHEMBL7476300 0.72 PIN1 (0.42) NR1H4NPSR1KDM4EHSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1224180-B1 SUBSTITUTED AZOLES NOVARTIS AG (CH) 2003-07-02 EP disclosed
US-6579874-B2 P38 MAP kinase inhibitors; treating Tumor necrosis factor (TNF-alpha) and Interleukin-1 mediated diseases, such as rheumatoid arthritis; imidazole and oxazole derivatives NOVARTIS AG (CH) 2003-06-17 US disclosed
EP-1224180-A2 SUBSTITUTED AZOLES Novartis AG (CH) 2002-07-24 EP disclosed
US-20020049220-A1 Substituted azoles NOVARTIS AG (CH) 2002-04-25 US disclosed
WO-2000063204-A2 SUBSTITUTED AZOLES NOVARTIS AG (CH) 2000-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049220-A1 Substituted azoles MAPK1, MAPK4, MAP3K1 DGAT1 2618/4885NR1H4 1107/4885NPSR1 1790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.